Lipoprotein(a) [Lp(a)] Blood Test

What Does This Test Measure?

Lp(a) is an LDL-like particle with an extra protein, apolipoprotein(a). It is ~90% genetically determined; diet and exercise have little impact. Elevated Lp(a) is an independent, causal risk factor for heart attack, stroke, and calcific aortic valve stenosis. It should be measured at least once in all adults.

Why Your Doctor Ordered This Test

Physicians order an Lp(a) test to uncover a hidden, genetically driven cardiovascular threat that standard lipid panels miss. Major guidelines, including the European Society of Cardiology/European Atherosclerosis Society, recommend measuring Lp(a) at least once in every adult, particularly in patients with premature atherosclerotic cardiovascular disease (ASCVD), a strong family history of early heart disease, recurrent events despite aggressive statin therapy, or intermediate/borderline risk where reclassification would change management. The test clarifies whether a person’s risk is driven by this highly heritable particle, independent of LDL cholesterol and other traditional factors.

The same measurement also helps evaluate the risk of calcific aortic valve stenosis, where Lp(a) accelerates valve calcification. Cascade screening of first-degree relatives of patients with elevated Lp(a) is advised because the trait is autosomal co-dominant and strongly clusters in families. Additionally, obtaining a baseline Lp(a) level guides decisions about intensifying modifiable risk-factor control, considering PCSK9 inhibitor therapy (which lowers Lp(a) ~25–30%), or, in extreme elevations, referring for lipoprotein apheresis. Without it, an entire stratum of residual risk remains invisible.

What High Lipoprotein [Lp] Means

High Lp(a) roughly doubles cardiovascular risk when >50 mg/dL. It promotes atherosclerosis, clot formation, and aortic valve calcification. No FDA-approved Lp(a)-specific medication exists yet (several in trials). Management: aggressive control of all other modifiable risk factors, LDL, blood pressure, lifestyle. PCSK9 inhibitors reduce Lp(a) ~25–30%. Lipoprotein apheresis available for extreme cases.

What Low Lipoprotein [Lp] Means

Low Lp(a) is genetically determined and protective. ~20–30% of people have very low levels. No clinical concern; these individuals have reduced lifetime cardiovascular risk.

How to Prepare and What Affects the Result

Fasting is not required for an Lp(a) blood test; concentrations are stable regardless of recent food intake. There is no diurnal variation, so the sample can be drawn at any time of day. However, because Lp(a) behaves as an acute-phase reactant, values can be falsely elevated during acute illness, infection, surgery, or myocardial infarction. Therefore, testing should ideally be scheduled when a person is clinically stable, at least two to three weeks after a major inflammatory event or acute coronary syndrome, to avoid a transient spike that does not represent the baseline genetically determined level. A standard serum or plasma specimen is acceptable, and the sample is stable under routine handling.

Several factors can subtly influence the result. Hormonal status matters: estrogen replacement and pregnancy lower Lp(a) by roughly 10–20%, while menopause is associated with higher levels. Certain medications also have small effects; statins may raise Lp(a) by 10–20% via upregulation of hepatic production, and niacin (though rarely used today for this purpose) lowers it. Because Lp(a) is overwhelmingly genetically fixed, repeat measurements are rarely needed once a reliable baseline is established, except to confirm borderline values or monitor the response to emerging therapies in clinical trials. Crucially, the assay method must measure Lp(a) independently of apo(a) isoform size, as polyclonal-antibody-based assays can underestimate concentrations in individuals with small isoforms, leading to misclassification.

Common Misinterpretations

A common mistake is believing that reaching LDL-cholesterol targets neutralizes the risk carried by elevated Lp(a). Even when LDL is driven below 70 mg/dL, high Lp(a) remains an independent, causal driver of atherothrombotic events and aortic valve stenosis. This occurs because Lp(a) carries pro-inflammatory oxidized phospholipids, promotes foam cell formation, and competes with plasminogen to inhibit fibrinolysis, fostering both atherosclerosis and thrombosis. Consequently, a patient with a normal lipid profile but Lp(a) above 50 mg/dL still faces roughly double the lifetime cardiovascular risk, a fact often overlooked.

Another major misinterpretation involves units of measurement. Lp(a) reported in mass units (mg/dL) cannot be interchanged with particle-number units (nmol/L). Because the mass-to-particle ratio depends on the genetically determined size of apolipoprotein(a), a fixed conversion factor will misclassify a significant proportion of people. A value of 50 mg/dL can correspond to particle numbers ranging from well below 125 nmol/L to far above, depending on isoform size. Clinicians sometimes treat the two thresholds as equivalent, leading to false reassurance or inappropriate alarm. Moreover, patients and providers occasionally assume that dietary changes or exercise can meaningfully lower Lp(a); in reality, the concentration is ~90% genetically determined, and lifestyle modification has negligible impact. Confusing Lp(a) with a modifiable risk factor diverts attention from the essential strategy of aggressively managing all other controllable cardiovascular risks.

Frequently Asked Questions

What is a dangerous level of lipoprotein(a)?

Levels above 50 mg/dL (or above 125 nmol/L) are considered high risk and roughly double the lifetime chance of heart attack, stroke, and calcific aortic valve stenosis. Borderline values fall between 30 and 50 mg/dL. Risk is continuous, not a simple on/off switch, but these cut-offs are used to identify people who need more intensive management of all other modifiable factors and, in some cases, inherited therapy. Because Lp(a) is largely genetic, a single measurement typically defines a person’s lifelong risk category.

How can I lower my lipoprotein(a) naturally?

Diet, exercise, and weight loss have very little effect on Lp(a) because roughly 90% of its concentration is fixed by your genes. There is no evidence that any specific food, supplement, or lifestyle intervention meaningfully reduces Lp(a). The primary strategy is to aggressively lower all other controllable cardiovascular risks (LDL cholesterol, blood pressure, and blood sugar) and to avoid smoking. For people with extreme elevations, PCSK9 inhibitor drugs lower Lp(a) by about 25–30%, while lipoprotein apheresis directly removes it from the blood.

Does lipoprotein(a) cause heart attacks?

Yes. Epidemiologic studies and genetic analyses confirm that high Lp(a) is an independent, causal risk factor for myocardial infarction. It promotes heart attacks through three main mechanisms: it deposits cholesterol in artery walls like LDL, carries pro-inflammatory oxidized phospholipids that accelerate plaque formation, and blocks the breakdown of blood clots by interfering with plasminogen activation. This combination of accelerated atherosclerosis and a pro-thrombotic environment makes coronary events more likely, even in people with otherwise normal cholesterol profiles.

Is fasting required for a lipoprotein(a) test?

No fasting is needed. Lp(a) concentration in blood does not change meaningfully after meals, so a non-fasting sample is fully acceptable and recommended by many current guidelines. Unlike triglycerides, which rise postprandially, Lp(a) remains stable. However, the test should not be drawn during an acute illness, after surgery, or during a heart attack because Lp(a) acts as an acute-phase reactant and can spike temporarily. For an accurate lifelong baseline, draw the sample when you are healthy and in your usual state.

Can statins increase lipoprotein(a)?

Some studies show that statin therapy can raise Lp(a) by about 10–20%, likely because statins upregulate the production of the LPA gene product in the liver. This modest increase has raised concern, but the net clinical benefit of aggressive LDL lowering with statins far outweighs any potential Lp(a)-related harm. In fact, the reduction in cardiovascular events from LDL lowering is so substantial that the slight rise in Lp(a) does not offset it. PCSK9 inhibitors, often added to statins, actively lower Lp(a).

Related Markers: Read Together for Full Context

BloodWorker reads lab values together, not in isolation. These related markers provide essential context for interpreting your Lipoprotein [Lp] result: